

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca</u> and according to acceptable standards of care

PROTOCOL CODE: LYBENDO Page 1 of 2

DOCTOR'S ORDERS Ht

___cm Wt_

kg BSA

m²

SIGNATURE:

UC:

 REMINDER:
 Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form

 DATE:
 To be given:
 Cycle #:

Date of Previous Cycle:

Delay treatment _____ week(s)

CBC & Diff Day 1 of treatment

Day 1: may proceed with doses as written, if within 96 hours: ANC greater than or equal to 0.8 x 10⁹/L and platelets greater than or equal to 80 x 10⁹/L

Proceed with treatment based on blood work from

PREMEDICATIONS: Patient to take own supply of oral medications. RN/Pharmacist to confirm

Cycle 1 Day 1

30 to 60 minutes prior to bendamustine: ondansetron 8 mg PO

30 minutes prior to bendamustine: dexamethasone 20 mg IV

30 minutes prior to oBINutuzumab (give during bendamustine infusion): acetaminophen 650 to 975 mg PO and diphenhydrAMINE 50 mg PO

Cycle 1 Day 2

30 to 60 minutes prior to bendamustine: ondansetron 8 mg PO and dexamethasone 28 mg or 212 mg PO (select one)

Cycle 1 Days 8 and 15

G0 minutes prior to oBINutuzumab, if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L before Cycle 1 Day 1: dexamethasone 20 mg IV
 30 minutes prior to oBINutuzumab: acetaminophen 650 to 975 mg PO and diphenhydrAMINE 50 mg PO

Cycles 2 to 6 Day 1

30 to 60 minutes prior to bendamustine: **ondansetron 8 mg** PO and **dexamethasone 🗌 8 mg** or **🗌 12 mg** PO (select one) If dexamethasone IV has been given for the oBINutuzumab premedication, then omit dexamethasone PO. **🗋** 30 minutes prior to bendamustine, if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L before Day 1 of current cycle: **dexamethasone 20 mg** IV

30 minutes prior to oBINutuzumab (give during bendamustine infusion): acetaminophen 650 to 975 mg PO and diphenhydrAMINE 50 mg PO

Cycles 2 to 6 Day 2

30 to 60 minutes prior to bendamustine: ondansetron 8 mg PO and dexamethasone 🗌 8 mg or 🗌 12 mg PO (select one)

Cycles 7 to 18:

 \Box 60 minutes prior to oBINutuzumab, if reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than 25 x 10⁹/L before Day 1 of current cycle: **dexamethasone 20 mg** IV

30 minutes prior to oBINutuzumab: acetaminophen 650 to 975 mg PO and diphenhydrAMINE 50 mg PO

Other:

DOCTOR'S SIGNATURE:



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYBENDO Page 2 of 2

Date:

** Have Hypersensitivity Reaction Tray and Protocol Available**

TREATMENT: INDUCTION PHASE: Cycle 1 to 6	
Cycle 1:	
Days 1 and 2: bendamustine 90 mg/m ² x BSA = mg IV in 250 to 500 mL NS over 1 hour on	Dave 1 and 2
oBINutuzumab 1000 mg IV in 250 mL NS on Day 1 only.	Days I and 2.
Start infusion at 50 mg/h ; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 4 occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table. For first dose, constant visual observation during dose increases and for 30 minutes after infusion	
signs not required unless symptomatic.	
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomford existing symptoms occur, stop infusion and page physician.	or exacerbation of any
Days 8 and 15:	
oBINutuzumab 1000 mg IV in 250 mL NS on Days 8 and 15. If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion faster: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increments minutes until rate = 400 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate titrate	of 100 mg/h every 30
Cycles 2 to 6:	
bendamustine 90 mg/m ² x BSA = mg on Days 1 and 2 . IV in 250 to 500 mL NS over 1 hour	
oBINutuzumab 1000 mg IV in 250 mL NS on Day 1 only. If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusio faster: Start at 100 mg/h . Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless protocol appendix for oBINutuzumab infusion rate titration table.	
MAINTENANCE PHASE	
oBINutuzumab 1000 mg IV in 250 mL NS on Day 1 . If no infusion reaction or only Grade 1 infusion reaction only in the previous infusion and final in faster: Start at 100 mg/h . Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless protocol appendix for oBINutuzumab infusion rate titration table.	
RETURN APPOINTMENT ORDERS	
 Cycle 1: Return in <u>four</u> weeks for Doctor and Cycle Book treatment on Days 1, 2, 3 Cycle 2 to 6: Return in <u>four</u> weeks for Doctor and Cycle Book treatment on Days 1 Cycle 7 to 18: Return in <u>two</u> months (calculate in months, not weeks) for Doctor and Cycle Last Cycle. Return in week(s). 	and 2.
CBC & Diff prior to Day 1 of each cycle	
If clinically indicated:	
Creatinine ALT total bilirubin HBV viral load	
☐ Other tests: ☐ Consults:	
See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC:

to

to

BC Cancer Provincial Preprinted Order LYBENDO

Created: 1 July 2018 Revised: 1 Mar 2025 (Premedications, observation, vitals and tests updated, treatment sequence changed)